Analysis of the relationship between resistin with prognosis, cell migration, and p38 and ERK1/2 activation in breast cancer

被引:0
|
作者
Cuachirria-Espinoza, Reyna L. [1 ]
Garcia-Miranda, Alin [1 ]
Hernandez-Barragan, Rafael [1 ]
Nava-Tapia, Dania A. [1 ]
Olea-Flores, Monserrat [1 ]
Navarro-Tito, Napoleon [1 ]
机构
[1] Univ Autonoma Guerrero, Fac Ciencias Quim Biol, Lab Biol Celular Canc, Ave Lazaro Cardenas S-N, Chilpancingo 39090, Gro, Mexico
关键词
Resistin; Prognosis; Cell migration; p38MAPK; ERK1/2; Breast cancer; EXPRESSION; SUBTYPES; TISSUE;
D O I
10.1016/j.biochi.2024.10.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Obesity increases the risk and mortality of breast cancer through dysregulated secretion of proinflammatory cytokines and tumor adipokines that induce an inflammatory breast microenvironment. Resistin is an adipokine secreted by adipocytes, immune cells, and predominantly macrophages, which contributes to cancer progression, but its molecular mechanism in cancer is not completely described. In this study, we analyzed the relationship of resistin on breast cancer prognosis and tumor progression and the effect in vitro of resistin on p38 and ERK1/2 activation in breast cancer cell lines. By bioinformatic analysis, we found that resistin is overexpressed in the basal subtype triple-negative breast cancer and is related to poor prognosis. In addition, we demonstrated a positive correlation between RETN and MAPK3 expression in basal triple-negative breast cancer. Importantly, we found amplifications of the RETN gene in at least 20 % of metastatic samples from patients with breast cancer. Most samples with RETN amplifications metastasized to bone and showed high expression of IL-8 (CXCL8) and IL-6 (IL6). Finally, resistin could be considered a prognostic marker for basal triple-negative breast cancer, and we also proposed the possibility that resistin-induced cell migration involves the activation of MAPK in breast cancer cells. (c) 2024 Elsevier B.V. and Soci & eacute;t & eacute; Fran & ccedil;aise de Biochimie et Biologie Mol & eacute;culaire (SFBBM). All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:19 / 29
页数:11
相关论文
共 50 条
  • [1] Inhibition of Hematopoietic Protein Tyrosine Phosphatase Augments and Prolongs ERK1/2 and p38 Activation
    Sergienko, Eduard
    Xu, Jian
    Liu, Wallace H.
    Dahl, Russell
    Critton, David A.
    Su, Ying
    Brown, Brock T.
    Chan, Xochella
    Yang, Li
    Bobkova, Ekaterina V.
    Vasile, Stefan
    Yuan, Hongbin
    Rascon, Justin
    Colayco, Sharon
    Sidique, Shyama
    Cosford, Nicholas D. P.
    Chung, Thomas D. Y.
    Mustelin, Tomas
    Page, Rebecca
    Lombroso, Paul J.
    Tautz, Lutz
    ACS CHEMICAL BIOLOGY, 2012, 7 (02) : 366 - 376
  • [2] MICAL2 promotes breast cancer cell migration by maintaining epidermal growth factor receptor (EGFR) stability and EGFR/P38 signalling activation
    Wang, Y.
    Deng, W.
    Zhang, Y.
    Sun, S.
    Zhao, S.
    Chen, Y.
    Zhao, X.
    Liu, L.
    Du, J.
    ACTA PHYSIOLOGICA, 2018, 222 (02)
  • [3] GABA(A) Receptor Pi (GABRP) Stimulates Basal-like Breast Cancer Cell Migration through Activation of Extracellular-regulated Kinase 1/2 (ERK1/2)
    Sizemore, Gina M.
    Sizemore, Steven T.
    Seachrist, Darcie D.
    Keri, Ruth A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (35) : 24102 - 24113
  • [4] The Effect of CacyBP/SIP on the Phosphorylation of ERK1/2 and p38 Kinases in Clear Cell Renal Cell Carcinoma
    Smereczanska, Magdalena
    Domian, Natalia
    Mlynarczyk, Grzegorz
    Kasacka, Irena
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (12)
  • [5] Flavopereirine induces cell cycle arrest and apoptosis via the AKT/p38 MAPK/ERK1/2 signaling pathway in human breast cancer cells
    Yeh, Hsuan-Te
    Tsai, Yi-Sheng
    Chen, Ming-Shan
    Li, Yi-Zhen
    Lin, Wen-Chun
    Lee, Ying-Ray
    Tseng, Ya-Shih
    Sheu, Shew-Meei
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 863
  • [6] TFPI inhibits breast cancer progression by suppressing ERK/p38 MAPK signaling pathway
    Xing, Mengying
    Yang, Ying
    Huang, Jiaxue
    Fang, Yaqun
    Jin, Yucui
    Li, Lingyun
    Chen, Xiang
    Zhu, Xiaoxia
    Ma, Changyan
    GENES & GENOMICS, 2022, 44 (07) : 801 - 812
  • [7] ERK1/2 and p38α/β Signaling in Tumor Cell Quiescence: Opportunities to Control Dormant Residual Disease
    Sosa, Maria Soledad
    Avivar-Valderas, Alvaro
    Bragado, Paloma
    Wen, Huei-Chi
    Aguirre-Ghiso, Julio A.
    CLINICAL CANCER RESEARCH, 2011, 17 (18) : 5850 - 5857
  • [8] Targeting the ERK1/2 and p38 MAPK pathways attenuates Golgi tethering factor golgin-97 depletion-induced cancer progression in breast cancer
    Liu, Yu-Chin
    Lin, Tsung-Jen
    Chong, Kowit-Yu
    Chen, Guan-Ying
    Kuo, Chia-Yu
    Lin, Yi-Yun
    Chang, Chia-Wei
    Hsiao, Ting-Feng
    Wang, Chih-Liang
    Shih, Yo-Chen
    Yu, Chia-Jung
    CELL COMMUNICATION AND SIGNALING, 2025, 23 (01)
  • [9] Amelogenin promotes odontoblast-like MDPC-23 cell differentiation via activation of ERK1/2 and p38 MAPK
    Yao, Naihui
    Li, Shiting
    Jiang, Yong
    Qiu, Songbo
    Tan, Yinghui
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2011, 355 (1-2) : 91 - 97
  • [10] Inhibition of fucosylation in human invasive ductal carcinoma reduces E-selectin ligand expression, cell proliferation, and ERK1/2 and p38 MAPK activation
    Carrascal, Mylene A.
    Silva, Mariana
    Ramalho, Jose S.
    Pen, Claudia
    Martins, Manuela
    Pascoal, Carlota
    Amaral, Constanca
    Serrano, Isabel
    Oliveira, Maria Jose
    Sackstein, Robert
    Videira, Paula A.
    MOLECULAR ONCOLOGY, 2018, 12 (05) : 579 - 593